Pharmacokinetics, pharmacodynamics, and immunogenicity of belatacept in adult kidney transplant recipients

Clinical Drug Investigation

Volumn 34, Issue 2, 2014, Pages 117-126

  Shen, Jinshan ^a   Townsend, Robert ^a   You, Xiaoli ^a   Shen, Yun ^a   Zhan, Ping ^a   Zhou, Zexun ^a   Geng, Dong ^a   Wu, Dianna ^a   McGirr, Nadia ^a   Soucek, Kathleen ^a   Proszynski, Elizabeth ^a   Pursley, Janice ^a   Masson, Eric ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BELATACEPT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; GRAFT RECIPIENT; HUMAN; IMMUNOGENICITY; IN VIVO STUDY; KIDNEY TRANSPLANTATION; LIMIT OF QUANTITATION; MAINTENANCE THERAPY; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; STEADY STATE;

ADULT; ANTIBODIES; ANTIGENS, CD86; AREA UNDER CURVE; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HALF-LIFE; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; TIME FACTORS;

EID: 84898985312     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-013-0153-2     Document Type: Article

References (24)

1. Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant. 2004;4(3):378-83. (Pubitemid 38282293)
2. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004;351(26):2715-29. (Pubitemid 39665325)
3. Schiff J, Cole E, Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol. 2007;2(2):374-84.
4. Nujolix® (belatacept) [package insert]. Princeton: Bristol-Myers Squibb Co.; 2013.
5. Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant. 2005;5(3):443-53. (Pubitemid 40313335)
6. Latek R, Fleener C, Lamian V, et al. Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation. Transplantation. 2009;87(6):926-33.
7. Paweletz C, Andersen JN, Pollock R, et al. Identification of direct target engagement biomarkers for kinase-targeted therapeutics. PLoS One. 2011;6(10):e26459.
8. Valencia X. An open-label pharmacokinetic study in de novo renal transplant subjects receiving a belatacept-based immuno-suppressant regimen. Princeton: Bristol-Myers Squibb; 2009. (Data on file).
9. Ferguson R, Grinyo J, Vincenti F, et al. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J Transplant. 2011;11(1):66-76.
10. Johnson A. Open-label, randomized, controlled, multiple-dose study of efficacy and safety of BMS-224818 as part of a quadruple drug regimen in renal transplant recipients (pharmacokinetic sub-study). Princeton: Bristol-Myers Squibb; 2008. (Data on file).
11. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010;10(3):535-46.
12. Larsen C, Grinyo J, Medina-Pestana J, et al. Belatacept-based regimens vs a cyclosporine-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation. 2010;90(12):1528-35.
13. Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant. 2010;10(3):547-57.
14. Vincenti F, Blancho G, Durrbach A, et al. Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol. 2010;21(9):1587-96.
15. Neoral® Soft Gelatin Capsules (cyclosporine capsules, USP) MODIFIED; Neoral® Oral Solution (cyclosporine oral solution, USP) MODIFIED [package insert]. Basel: Novartis International AG; 2012.
16. Myler H, Phillips KR, Dong H, et al. Validation and life-cycle management of a quantitative ligand-binding assay for the measurement of Nulojix®, a CTLA-4-Fc fusion protein, in renal and liver transplant patients. Bioanalysis. 2012;4(10):1215-26.
17. Zhou Z, Shen J, Hong Y, et al. Time-varying belatacept exposure and its relationship to efficacy/safety responses in kidney-transplant recipients. Clin Pharmacol Ther. 2012;92(2):251-7.
18. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med. 2005;353(8):770-81. (Pubitemid 41215486)
19. Shen J, Townsend R, Kaul S. An integrated approach to develop belatacept dosing regimens for phase 3 studies in renal transplant subjects [abstract no. OII-A-4]. Clin Pharmacol Ther. 2011;89(Suppl 1):S37.
20. Grinyo J, Charpentier B, Pestana JM, et al. An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation. 2010;90(12):1521-7.
21. Wadhwa M, Thorpe R. Unwanted immunogenicity: lessons learned and future challenges. Bioanalysis. 2010;2(6):1073-84.
22. Kuypers DR. Immunotherapy in elderly transplant recipients: a guide to clinically significant drug interactions. Drugs Aging. 2009;26(9):715-37.
23. Seitz K, Zhou H. Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check. J Clin Pharmacol. 2007;47:1104-18.
24. Lee J-I, et al. CYP-mediated therapeutic protein-drug interactions. Clin Pharmacokinet. 2010;49(5):295-310.